Literature DB >> 22844547

Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention.

Siddavaram Nagini1.   

Abstract

Carcinoma of the stomach is still the second most common cause of cancer death worldwide, although the incidence and mortality have fallen dramatically over the last 50 years in many regions. The incidence of gastric cancer varies in different parts of the world and among various ethnic groups. Despite advances in diagnosis and treatment, the 5-year survival rate of stomach cancer is only 20 per cent. Stomach cancer can be classified into intestinal and diffuse types based on epidemiological and clinicopathological features. The etiology of gastric cancer is multifactorial and includes both dietary and nondietary factors. The major diet-related risk factors implicated in stomach cancer development include high content of nitrates and high salt intake. Accumulating evidence has implicated the role of Helicobacter pylori (H. pylori) infection in the pathogenesis of gastric cancer. The development of gastric cancer is a complex, multistep process involving multiple genetic and epigenetic alterations of oncogenes, tumor suppressor genes, DNA repair genes, cell cycle regulators, and signaling molecules. A plausible program for gastric cancer prevention involves intake of a balanced diet containing fruits and vegetables, improved sanitation and hygiene, screening and treatment of H. pylori infection, and follow-up of precancerous lesions. The fact that diet plays an important role in the etiology of gastric cancer offers scope for nutritional chemoprevention. Animal models have been extensively used to analyze the stepwise evolution of gastric carcinogenesis and to test dietary chemopreventive agents. Development of multitargeted preventive and therapeutic strategies for gastric cancer is a major challenge for the future.

Entities:  

Keywords:  Chemoprevention; Diet; Epidemiology; Epigenetic changes; Gastric cancer; Genetic alterations; Helicobacter pylori; Risk factors

Year:  2012        PMID: 22844547      PMCID: PMC3406280          DOI: 10.4251/wjgo.v4.i7.156

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  151 in total

1.  MicroRNA signatures in Helicobacter pylori-infected gastric mucosa.

Authors:  Kayoko Matsushima; Hajime Isomoto; Naoki Inoue; Toshiyuki Nakayama; Tomayoshi Hayashi; Masaaki Nakayama; Kazuhiko Nakao; Toshiya Hirayama; Shigeru Kohno
Journal:  Int J Cancer       Date:  2010-03-23       Impact factor: 7.396

2.  Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer.

Authors:  K Hayashi; H Yokozaki; S Goodison; N Oue; T Suzuki; R Lotan; W Yasui; E Tahara
Journal:  Differentiation       Date:  2001-08       Impact factor: 3.880

3.  Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer.

Authors:  Eliseo Mattioli; Paraskevi Vogiatzi; Ang Sun; Giovanni Abbadessa; Giulia Angeloni; Domenico D'Ugo; Daniela Trani; John P Gaughan; Fabio Maria Vecchio; Gabriele Cevenini; Roberto Persiani; Antonio Giordano; Pier Paolo Claudio
Journal:  J Cell Physiol       Date:  2007-01       Impact factor: 6.384

4.  Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study.

Authors:  Carlos A Gonzalez; Elio Riboli
Journal:  Eur J Cancer       Date:  2010-09       Impact factor: 9.162

Review 5.  Helicobacter pylori infection causes gastric cancer? A review of the epidemiological, meta-analytic, and experimental evidence.

Authors:  Guy-D Eslick
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

Review 6.  Gastric cancer.

Authors:  Vincenzo Catalano; Roberto Labianca; Giordano D Beretta; Gemma Gatta; Filippo de Braud; Eric Van Cutsem
Journal:  Crit Rev Oncol Hematol       Date:  2009-02-20       Impact factor: 6.312

7.  A hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer.

Authors:  Byung Lan Lee; Woo Ho Kim; Jieun Jung; Sung Jin Cho; Jong-Wan Park; Jihyen Kim; Hee-Yong Chung; Mee Soo Chang; Seon Young Nam
Journal:  Carcinogenesis       Date:  2007-11-04       Impact factor: 4.944

8.  Cigarette smoking reduces human gastric luminal prostaglandin E2.

Authors:  D R McCready; L Clark; M M Cohen
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

9.  Eugenol inhibits cell proliferation via NF-κB suppression in a rat model of gastric carcinogenesis induced by MNNG.

Authors:  P Manikandan; G Vinothini; R Vidya Priyadarsini; D Prathiba; S Nagini
Journal:  Invest New Drugs       Date:  2009-10-23       Impact factor: 3.850

10.  Trends in cancer incidence in esophagus, stomach, colon, rectum and liver in males in India.

Authors:  Balkrishna B Yeole
Journal:  Asian Pac J Cancer Prev       Date:  2008 Jan-Mar
View more
  160 in total

1.  Association between Interleukin-8-251A/T polymorphism and gastric cancer susceptibility: a meta-analysis based on 5286 cases and 8000 controls.

Authors:  Yafei Zhang; Xianling Zeng; Hongwei Lu; Yiming Li; Hong Ji
Journal:  Int J Clin Exp Med       Date:  2015-12-15

2.  Role of hMLH1 and E-cadherin promoter methylation in gastric cancer progression.

Authors:  Meysam Moghbeli; Omeed Moaven; Bahram Memar; Hamid Reza Raziei; Azadeh Aarabi; Ezzat Dadkhah; Mohammad Mahdi Forghanifard; Fatemeh Manzari; Mohammad Reza Abbaszadegan
Journal:  J Gastrointest Cancer       Date:  2014-03

3.  MiRNA-27a promotes the proliferation and invasion of human gastric cancer MGC803 cells by targeting SFRP1 via Wnt/β-catenin signaling pathway.

Authors:  Fang Wu; Jun Li; Ni Guo; Xiao-Hui Wang; Yu-Qian Liao
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

Review 4.  Inhibition of Hedgehog signaling in the gastrointestinal tract: targeting the cancer microenvironment.

Authors:  Juanita L Merchant; Milena Saqui-Salces
Journal:  Cancer Treat Rev       Date:  2013-08-13       Impact factor: 12.111

5.  Prognostic impact of microscopic tumor involved resection margin in advanced gastric cancer patients after gastric resection.

Authors:  Jung-Woo Woo; Keun Won Ryu; Ji Yeon Park; Bang Wool Eom; Mi Jung Kim; Hong Man Yoon; Sook Ryun Park; Myeong-Cherl Kook; Il Ju Choi; Young-Woo Kim; Young-Iee Park
Journal:  World J Surg       Date:  2014-02       Impact factor: 3.352

6.  Ataxin-3 expression correlates with the clinicopathologic features of gastric cancer.

Authors:  Li-Xia Zeng; Yong Tang; Yun Ma
Journal:  Int J Clin Exp Med       Date:  2014-04-15

Review 7.  Diabetes and gastric cancer: the potential links.

Authors:  Chin-Hsiao Tseng; Farn-Hsuan Tseng
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

8.  Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.

Authors:  Gianluca Tomasello; Wanda Liguigli; Rossana Poli; Silvia Lazzarelli; Matteo Brighenti; Federica Negri; Alessandra Curti; Mario Martinotti; Lucio Olivetti; Massimo Rovatti; Gianvito Donati; Rodolfo Passalacqua
Journal:  Gastric Cancer       Date:  2013-11-27       Impact factor: 7.370

9.  Susceptibility to Helicobacter pylori infection: results of an epidemiological investigation among gastric cancer patients.

Authors:  Nikola Panic; Elena Mastrostefano; Emanuele Leoncini; Roberto Persiani; Dario Arzani; Rosarita Amore; Riccardo Ricci; Federico Sicoli; Stefano Sioletic; Milutin Bulajic; Domenico D' Ugo; Walter Ricciardi; Stefania Boccia
Journal:  Mol Biol Rep       Date:  2014-02-14       Impact factor: 2.316

10.  Advances in gastric cancer prevention.

Authors:  Antonio Giordano; Letizia Cito
Journal:  World J Clin Oncol       Date:  2012-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.